肝硬化门静脉血栓形成机制、自发性再通和抗凝治疗研究进展*

doi:10.3969/j.issn.1672-5069.2025.06.001

Abstract

Yao Yu, Ning Bo. Pathogenesis,spontaneous recanalization and anticoagulation therapy in patients with liver cirrhosis and portal vein thrombosis[J]. Journal of Practical Hepatology, 2025, 28(6): 801-804.

References

[1] Senzolo M, Garcia-Tsao G, Garcia-Pagan JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021,75(2):442-453.
[2] Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020,Shanghai). J Dig Dis,2021,22(4):176-186.
[3] Faccia M, Ainora ME, Ponziani FR, et al. Portal vein thrombosis in cirrhosis:why a well-known complication is still matter of debate. World J Gastroenterol,2019,25(31):4437.
[4] Serper M, Weinberg EM, Cohen JB, et al. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology,2021,73(1):219-232.
[5] Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol,2021,75(6):1367-1376.
[6] Maruyama H, Okugawa H, Takahashi M, et al. De novoportal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol,2013,108(4):568-574.
[7] Sacchetti S, Puricelli C, Mennuni M, et al.Research into new molecular mechanisms in thrombotic diseases paves the way for innova-tive therapeutic approaches. Int J Mol Sci,2024,25(5):2523.
[8] Brusilovskaya K, Hofer BS, Simbrunner B, et al. Platelet function decreases with increasing severity of liver cirrhosis and portal hypertension-a prospective study. Thromb Haemost,2023,123(12):1140-1150.
[9] Zifkos K, Dubois C, Schäfer K. Extracellular vesicles and thrombosis: update on the clinical and experimental evidence. Int J Mol Sci,2021,22(17):9317.
[10] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin‐rich thrombus. Hepatology,2022,75(4):898-911.
[11] 崔冶齐,张世斌.肝硬化门静脉血栓分类及形成机制研究进展.实用肝脏病杂志,2025,28(2):161-164.
[12] Kang H, Kim S, Park S, et al. Small leucine zipper protein negatively regulates liver fibrosis by suppressing the expression of plasminogen activator inhibitor-1. Exp Cell Res,2024,442(2):114258.
[13] Scheiner B, Balcar L, Nussbaumer RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol,2022,76(5):1090-1099.
[14] Zhang Y, Liang X, Bao X, et al. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective. Eur J Med Chem,2022,235:114291.
[15] Li W, Chang N, Li L. Heterogeneity and function of Kupffer cells in liver injury. Front Immunol,2022,13:940867.
[16] 靳珂珂,丁惠国.肝硬化门静脉血栓形成风险监测及抗凝管理.实用肝脏病杂志,2024,27(1):3-6.
[17] Hassnine AA, Elsayed AM. COVID‐19 in cirrhotic patients: is portal vein thrombosis a potential complication? Can J Gastroenterol Hepatol,2022, 2022(1):5900468.
[18] Nery F, Carneiro P, Correia S, et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. Eur J Gastroenterol Hepatol,2021,33(1S):e108-e113.
[19] Xing Y, Tian Z, jiang Y, et al.A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis. Ann Med,2022,54(1):302-309.
[20] 李玲,陆申新,崔春晓,等.591例肝硬化患者门静脉血栓形成的危险因素分析.复旦学报(医学版),2017,44(03):288-293.
[21] Gîrleanu I, Trifan A, Cojocriu C, et al. The risk of thrombotic events in patients with liver cirrhosis. Rev Med Chir Soc Med Nat Lasi,2012,116(4):991-996.
[22] Ak C, Adali G, Sayar S, et al. Portal vein thrombosis risk factors in liver transplant candidates. Hepatol Forum,2022,3(3):88.
[23] Gaballa D, Bezinover D, Kadry Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index. Liver Transpl,2019,25(12):1747-1755.
[24] Qi X, Han G, Ye C, et al. Splenectomy causes 10-fold increased risk of portal venous system thrombosis in liver cirrhosis patients.Med Sci Monit,2016,22:2528.
[25] Xu X, Guo X, De Stefano V, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int,2019,13:468-481.
[26] Qi X, Guo X, Yoshida EM, et al. Transient portal vein thrombosis in liver cirrhosis. BMC Ded,2018,16:1-11.
[27] Giri S, Singh A, Kolhe K, et al. Natural history of portal vein thrombosis in cirrhosis:a systematic review with Meta‐analysis.J Gastroenterol Hepatol,2023,38(10):1710-1717.
[28] Yokoyama S, Ishizu Y, Honda T, et al. Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis. Hepatol Res,2022,52(2):199-209.
[29] Xu S, Guo X, Xu X, et al. Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis.Eur J Gastroenterol Hepatol,2021,33(1S):e423-e430.
[30] Nicoară-Farcău O, Soy G, Magaz M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis. Semin Thromb Hemost,2020,46(06):673-681.
[31] Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology,2012,265(1):124-132.
[32] Yao C, Zhao M, Ibrahim B, et al. Anticoagulation for the treatment of portal vein thrombosis in cirrhosis: a systematic review and meta-analysis of comparative studies. J Clin Exp Hepatol,2023,13(3):404-413.
[33] Scheiner B, Stammet PR, Pokorny S, et al.Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.Wien Klin Wochenschr,2018,130(13-14):446-455.
[34] Guerrero A, Del Campo L, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis:the importal competing-risk Meta-analysis. J Hepatol,2023,79(1):69-78.
[35] Lisman T.Treatment of portal vein thrombosis in cirrhosis with anticoagulation—more than meets the eye? Hepatobiliary Surg Nutr,2024,13(2):321.
[36] Senzolo M, Garcia-Pagan JC. A major research gap: the use of anticoagulants in cirrhosis. J Hepatol,2023,79(6):1566-1570.
[37] Noronha Ferreira C, Reis D, Cortez-Pinto H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis. Dig Dis Sci,2019,64:2671-2683.

Pathogenesis,spontaneous recanalization and anticoagulation therapy in patients with liver cirrhosis and portal vein thrombosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Peng Dongmei, Wang Dong, Xie Xiaojun. Predictive efficacy of ascites polymorphonuclear leucocyte counts and systemic immune-inflammation index and serum CRP/ALB ratio for spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(6): 874-877.
[2]	Huang Xiaoli, Shen Jie. Entecavir antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(6): 878-881.
[3]	Lu Tao, Li Jiaguo, Li Shiwei, et al. Risk factors influencing portal vein thrombosis after splenectomy and portoazygous devascularization in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(6): 882-885.
[4]	Chen Shanshan, Si Xiaochuang, Zhu Jiabao, et al. Diagnostic performance of liver shear wave velocity and various noninvasive parameter combination in the assessment of liver cirrhosis in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2025, 28(6): 886-889.
[5]	Liang Shengkai, Yin Xiaochun, Zhang Feng, et al. Hepatic sinusoidal obstruction syndrome induced by gynura segetum with portal vein thrombosis: A case report and literature review [J]. Journal of Practical Hepatology, 2025, 28(6): 954-956.
[6]	Zhu Yingjing, Wu Jie, Tian Xinyue, et al. Endoscopic tissue glue injection and esophageal variceal ligation in treatment of patients with hepatitis B-induced liver cirrhosis and esophageal and gastric varices bleeding [J]. Journal of Practical Hepatology, 2025, 28(5): 731-734.
[7]	Chen Jie, Yang Caimin, Peng Cailing, et al. Evaluation of histological changes based on Beijing standard in patients with hepatitis B-induced liver cirrhosis during entecavir antiviral therapy [J]. Journal of Practical Hepatology, 2025, 28(5): 735-738.
[8]	Wang Chuang, Zhou Lin, Gao Huanhuan, et al. Predictive performance of thromboelastogram parameters and blood coagulation indexes for portal vein thrombosis in patients with liver cirrhosis after splenectomy [J]. Journal of Practical Hepatology, 2025, 28(5): 739-742.
[9]	Li Jialiang, Duan Yan, Shen Jian, et al. Diagnosis of cirrhotic cardiomyopathy in patients with hepatitis B-induced liver cirrhosis by Doppler tissue imaging and echocardiography [J]. Journal of Practical Hepatology, 2025, 28(5): 743-746.
[10]	Wang Huifang, Huang Shiquan, Tian Juan. CT scan for determination of portal vein system thrombosis in patients with hepatitis B cirrhosis and hypersplenism after partial splenic artery embolization [J]. Journal of Practical Hepatology, 2025, 28(5): 747-750.
[11]	Xu Fenghua, Peng Le, Xu Ning. Prediction of re-bleeding by platelet-to-albumin ratio and Charlson comorbidity index in cirrhotics with esophageal variceal bleeding after first hemostasis [J]. Journal of Practical Hepatology, 2025, 28(4): 581-584.
[12]	Shi Haiqun, Qian Jie, Shen Guoqian, et al. Satisfactory response to sofosbuvir and velpatasvir combination regimen in patients with hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(4): 585-588.
[13]	Gao Xiaoting, Gao Xin, Liu Yanli, et al. Comparison of conventional ultrasonography and contrast-enhanced ultrasonography in assessing stent function in patients with cirrhotics with portal hypertension after TIPS treatment [J]. Journal of Practical Hepatology, 2025, 28(4): 589-592.
[14]	Zhai Feifei, Wang Cai, Wang Junling, et al. Diagnostic performance of sound touch elastography and semi-quantitative ultrasound scoring in assessing early liver cirrhosisin patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(3): 402-405.
[15]	Yao Yu, Xu Chunyang, Ren Jiangwu. Prevalence and risk factors of overt hepatic encephalopathy in hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(3): 406-409.